These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 3699079

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Metabolism and pharmacokinetics of dibromodulcitol (DBD, NSC-104800) in man--II. pharmacokinetics of DBD.
    Horváth IP, Csetényi J, Hindy I, Kerpel-Fronius S, Institoris I, Hegedüs I, Eckhardt S.
    Eur J Cancer Clin Oncol; 1982 Nov; 18(11):1211-9. PubMed ID: 6891658
    [Abstract] [Full Text] [Related]

  • 3. Clinical trials with the hexitol derivatives in the U.S.
    Chiuten DF, Rozencweig M, Von Hoff DD, Muggia FM.
    Cancer; 1981 Feb 01; 47(3):442-51. PubMed ID: 6784907
    [Abstract] [Full Text] [Related]

  • 4. Chemotherapeutic approaches to brain tumors. Experimental observations with dianhydrogalactitol and dibromodulcitol.
    Levin VA, Wheeler KT.
    Cancer Chemother Pharmacol; 1982 Feb 01; 8(1):125-31. PubMed ID: 7094198
    [Abstract] [Full Text] [Related]

  • 5. Rat liver-mediated degradation of dibromodulcitol.
    Csetényi J, Gáti E, Hegedüs L, Horváth IP, Holczinger L.
    Eur J Cancer Clin Oncol; 1985 Jul 01; 21(7):881-5. PubMed ID: 4043174
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of dibromodulcitol in humans: a phase I study.
    Kelley SL, Peters WP, Andersen J, Furlong EA, Frei E, Henner WD.
    J Clin Oncol; 1986 May 01; 4(5):753-61. PubMed ID: 3517245
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacokinetic study in a phase I trial with an alkylating agent, diacetyldianhydrogalactitol (DADAG).
    Erdélyi-Tóth V, Kerpel-Fronius S, Kanyár B, Eckhardt S.
    Cancer Chemother Pharmacol; 1986 May 01; 16(3):257-63. PubMed ID: 3698167
    [Abstract] [Full Text] [Related]

  • 9. Interaction of GGCC sequences of DNA with anticancer dianhydrogalacticol, detected by inhibition of restriction enzyme BspI.
    Financsek I, Guczi J, Hidvégi EJ.
    Acta Biochim Biophys Acad Sci Hung; 1984 May 01; 19(3-4):177-84. PubMed ID: 6100663
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Metabolism and pharmacokinetics of dibromodulcitol (DBD, NSC-104800) in man. I. Metabolites of DBD.
    Horváth IP, Csetényi J, Kerpel-Fronius S, Hindy I, Eckhardt S.
    Eur J Cancer (1965); 1979 Mar 01; 15(3):337-44. PubMed ID: 446515
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Complex evaluation of the effect of some cytostatic hexitol derivatives.
    Holczinger L, Somfai-Relle S, Institoris E, Gáti E, Turi G.
    Oncology; 1980 Mar 01; 37 Suppl 1():104-8. PubMed ID: 7454197
    [Abstract] [Full Text] [Related]

  • 16. Incorporation of 3H-dibromodulcitol and 3H-dianhydrodulcitol into ascites tumor cells. Autoradiographic study.
    Kopper L, Lapis K, Institóris L.
    Neoplasma; 1976 Mar 01; 23(1):47-52. PubMed ID: 1272473
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.